Cogentix Medical is a global company that provides urology, gynecology, bariatric medicine, critical care, otolaryngology, pulmonology and gastroenterology technologies.
Here are five things to know.
1. The Minnetonka, Minn.-based company was formed after Vision-Sciences and Uroplasty merged in 2015. Uroplasty focused on bulking agents and office-based neuromodulation, and Vision-Sciences introduced a sterile, sheathed-endoscope technology.
2. The PrimeSight transnasal esophagoscopy system is Cogentix Medical's flagship GI product. The system offers on-the-spot biopsy capability and combines endoscope technology with the sterile EndoSheath protective barrier for immediate diagnosis of the esophageal anatomy.
3. Cogentix Medical agreed to an acquisition bid from Laborie Medical Technologies. Laborie will pay $235 million to acquire Cogentix, approximately $3.85 per share of outstanding stock.
4. Laborie will pay a 28 percent premium over Cogentix' average 30-day closing price.
5. Darrin Hammers has served as the president and CEO of Cogentix Medical since July 2016. Mr. Hammers joined Cogentix' predecessor company Uroplasty as vice president of global sales in May 2013.
More articles on gastroenterology:
The end of colonoscopies? Blood test identifies colon polyps